Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19

Abstract Background The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Sacha Satram, Parima Ghafoori, Carolina M. Reyes, Tom J. H. Keeley, Helen J. Birch, Dimitra Brintziki, Melissa Aldinger, Elizabeth Alexander, Amanda Lopuski, Elias H. Sarkis, Anil Gupta, Adrienne E. Shapiro, John H. Powers
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: SpringerOpen 2023-09-01
Loạt:Journal of Patient-Reported Outcomes
Những chủ đề:
COVID-19
FLU-PRO Plus
Monoclonal antibody
Patient-reported outcomes
PRO
Sotrovimab
Truy cập trực tuyến:https://doi.org/10.1186/s41687-023-00621-8

Internet

https://doi.org/10.1186/s41687-023-00621-8

Những quyển sách tương tự